| [2] Fried MW,Shiffman ML,Reddy KR, et al.Peginterferon -2a plus ribavirin for chronic hepatitis C virus infection[J].N Eng J Med,2002,347( 13):975-982. | |
| [2] | Manns MP,McHutchison JG,Gordon SC, et al.Peginterferon -2b plus ribabirin compared with interferon -2b plus ribavirin for initial treatment of chronic heptatitis C: a randomized trial[J].Lancet,2001, 358( 9286):958-965. |
| [3] 中华医学会肝脏病学会,中华医学会传染病与寄生虫分会.丙型肝炎防治指南[J].中华肝脏病杂志,2004,12 ( 4 ):194-198. | |
| [4] Poordad FF.Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C[J].Aliment Pharmacol Ther,2010,31( 12):1251-1267. | |
| [5] Reddy KR,Messinger D,Popescu M,et al.Peginterferon -2a ( 40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients[J].J Viral Hepat,2009, 16( 10):724-731. | |
| [6] Lu L,Nakano T,He Y,et al.Heptatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants[J].J Med Virol, 2005, 75( 4):538-549. | |
| [7] Perry CM, Jarvis B.Peginterferon--2a( 40KD):a review of its use in the management of chronic hepatitis C[J].Drugs,2001,61(5):2263-2288. | |
| [8] Liu CH,Liu CJ,Lin CL,et al.Pegylated interferon--2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infecton: a multicenter, randomized controlled trial[J].Clin Infect Dis,2008,47( 10):1260-1269. | |
| [9] Ferenci P,Fried MW,Shiffman ML,et al.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon -2a ( 40KD ) /ribabirin [J].J Hepatol,2005,43( 3):425-433. | |
| [10] Sanchez-Tapias JM,Diago M,Escartin P, et al.Peginterferon -2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatits C virus RNA at week 4 of treatment[J].Gastroenterology,2006, 131( 2):451-460. | |
| [11] 李明慧,陈立军,邱国华,等.快速病毒学应答对干扰素治疗慢性丙型肝炎疗效的预测分析[J].中华肝脏病杂志,2009,17( 7):497-500. |